

# Ulrike K Buchwald

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5588236/publications.pdf>

Version: 2024-02-01

17  
papers

248  
citations

1163117  
8  
h-index

996975  
15  
g-index

17  
all docs

17  
docs citations

17  
times ranked

208  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>Cryptococcus neoformans</i> infection in malignancy. <i>Mycoses</i> , 2016, 59, 542-552.	4.0	55
2	A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). <i>Vaccine</i> , 2022, 40, 162-172.	3.8	40
3	Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence. <i>Expert Review of Vaccines</i> , 2021, 20, 243-256.	4.4	33
4	Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged 50 years: A randomized phase III trial (PNEU-PATH). <i>Vaccine</i> , 2021, 39, 6422-6436.	3.8	25
5	Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV. <i>Aids</i> , 2022, 36, 373-382.	2.2	15
6	The importance of anal cancer screening and high-resolution anoscopy to gastroenterology practice. <i>Current Opinion in Gastroenterology</i> , 2020, 36, 393-401.	2.3	11
7	Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature. <i>Expert Review of Vaccines</i> , 2021, 20, 257-267.	4.4	10
8	Sequential administration of Prevnar 13 and PNEUMOVAX 23 in healthy participants 50 years of age and older. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2678-2690.	3.3	10
9	Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged 50 years: a randomized phase 3 trial (PNEU-FLU). <i>Human Vaccines and Immunotherapeutics</i> , 2021, , 1-14.	3.3	10
10	Active Tuberculosis Case Finding in Port-au-Prince, Haiti: Experiences, Results, and Implications for Tuberculosis Control Programs. <i>Tuberculosis Research and Treatment</i> , 2016, 2016, 1-11.	0.6	9
11	Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY). <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab605.	0.9	9
12	Anal Cancer Screening in an Urban HIV Clinic. <i>Journal of the International Association of Providers of AIDS Care</i> , 2015, 14, 497-504.	1.5	8
13	Establishing an Anal Cancer Screening Program in an Outpatient HIV Clinic: Referral Patterns and Patient Perceptions Survey. <i>Journal of the International Association of Providers of AIDS Care</i> , 2020, 19, 232595821989953.	1.5	5
14	Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged 50 years: A randomized phase 3 trial (PNEU-TRUE). <i>Vaccine</i> , 2022, 40, 1342-1351.	3.8	5
15	Pelvic squamous cell cancer in an HIV-infected man with a history of high-grade anal dysplasia. <i>International Journal of Colorectal Disease</i> , 2016, 31, 1079-1080.	2.2	2
16	Response to Vyse et al., "A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK". <i>Expert Review of Vaccines</i> , 2022, , 1-2.	4.4	1
17	Further Considerations on the Natural History of Anal Dysplasia in Response to Jongen et al and Barroso. <i>Journal of Infectious Diseases</i> , 2021, 224, 1270-1271.	4.0	0